EMCITATE

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
EMCITATE
Generic name
TIRATRICOL
Manufacturer
Rare Thyroid Therapeutics International AB
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
48d9faab-9c60-4abd-b4b9-97ffa778c944
SPL ID
53a695c9-d49c-4fe9-bcf6-0fd702667480
Version
1
Effective date
2026-10-01
Source export date
2026-11-13
Source partition
7
Source file
https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/875ce92e4370b2000cf566c8a9c0e4d02cceccd3a3b18a8b0b87928b28506f0b/drug-label-0007-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:34:50
Harmonized routes table
Harmonized routes
ORAL

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Boxed warning sections page 1 of 1 · 1 matching rows.

boxed warning

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including EMCITATE, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss [see Warnings and Precautions ( 5.2 )]. WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS See full prescribing information for complete boxed warning. Thyroid hormones, including EMCITATE, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. ( 5.2 )

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Thyrotoxicosis : Signs and symptoms of thyrotoxicosis (e.g., increased heart rate, elevated blood pressure, diarrhea, hyperhidrosis, irritability, insomnia, nightmares) have occurred with EMCITATE during treatment initiation and dose titration. Monitor and adjust the EMCITATE dose as indicated. ( 5.1 ) Laboratory Test Interference for T3 Measurement : Tiratricol can cross-react with immunoassays for T3 leading to unreliable T3 results and cause an overestimation of T3. ( 5.3 ) 5.1 New Onset or Worsening of Thyrotoxicosis Signs and symptoms of thyrotoxicosis, such as increased heart rate, elevated blood pressure, diarrhea, hyperhidrosis, irritability, insomnia, and nightmares, have occurred in patients receiving EMCITATE [see Adverse Drug Reactions ( 6.1 )] . These symptoms may occur if the EMCITATE dose is further increased despite T3 normalization, due to a drug-induced thyromimetic effect [see Dosage and Administration ( 2 )] . Signs and symptoms of thyrotoxicosis may also occur during the dose titration period due to a combined thyromimetic effect from endogenous T3 levels that have not yet declined and EMCITATE. If signs and symptoms of thyrotoxicosis occur despite T3 level normalization, decrease the EMCITATE dose according to the dose titration schedule [see Dosage and Administration ( 2.4 )] . If signs and symptoms of thyrotoxicosis do not resolve within 2 weeks after dose down-titration, the dose should be further reduced [see Dosage and Administration ( 2.3 , 2.4 )] . 5.2 Not for Treatment of Obesity or Weight Loss EMCITATE should not be taken for weight reduction as it may cause symptoms of thyrotoxicosis that could be serious or life-threatening. 5.3 Laboratory Test Interference for T3 Measurement Tiratricol can cross-react with T3 immunoassays leading to unreliable T3 results. When present, such cross-reactivity causes an overestimation of T3. Cross-reactivity of tiratricol is not expected to impact measurement of T3 by LC-MS/MS. An FDA-authorized LC-MS/MS test for the measurement of total T3 is not currently available.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS Most common adverse reactions (≥ 5%): diarrhea, vomiting, rash, and hyperhidrosis. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Egetis Therapeutics US Inc. at 1-844-4EGETIS (1-844-434-3847) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of EMCITATE in patients with MCT8 deficiency was evaluated in two studies. Study 1 (NCT05579327) was a 3-period, multicenter study with an up to 16-week, open-label, titration period followed by a 30-day randomized double-blind, placebo-controlled withdrawal period, then a 6-week open-label treatment period. Study 1 enrolled 20 male patients with MCT8 deficiency. Study 2 (NCT02060474) was an open-label, single-arm, multicenter study of 12 months duration that enrolled 46 male patients with MCT8 deficiency [see Clinical Studies ( 14 )] . Adverse reactions reported in ≥ 5% of patients treated with EMCITATE are summarized in Table 1 . Table 1. Adverse Drug Reactions in ≥ 5% of Patients in Study 1 and Study 2 Adverse Reactions Study 1 EMCITATE N = 20 n (%) Study 2 EMCITATE N = 46 n (%) Diarrhea 0 6 (13) Vomiting 2 (10) 5 (11) Rash 2 (10) 4 (9) Hyperhidrosis 1 (5) 3 (7) Signs and symptoms of thyrotoxicosis In Study 2, transient increases in heart rate (≥ 10 bpm) and systolic blood pressure (≥ 5 mmHg) were observed in 35% and 26% of participants, respectively, during the titration period. In addition, 30% of participants experienced at least one adverse reaction potentially related to thyrotoxicosis during the trial (diarrhea, hyperhidrosis, irritability, insomnia, nightmares), with most of these adverse reactions occurring during the titration period [see Warnings and Precautions ( 5.1 )].

adverse reactions table

<table ID="t1" width="100%"> <caption>Table 1. Adverse Drug Reactions in &#x2265; 5% of Patients in Study 1 and Study 2 </caption> <col width="33.333%" align="left"/> <col width="33.333%" align="left"/> <col width="33.333%" align="left"/> <tbody> <tr> <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> <content styleCode="bold">Adverse Reactions</content> </td> <td align="center" valign="top" styleCode="Toprule Botrule Rrule"> <content styleCode="bold">Study 1</content> <content styleCode="bold">EMCITATE</content> <content styleCode="bold">N = 20</content> <content styleCode="bold">n (%)</content> </td> <td align="center" valign="top" styleCode="Toprule Botrule Rrule"> <content styleCode="bold">Study 2</content> <content styleCode="bold">EMCITATE</content> <content styleCode="bold">N = 46</content> <content styleCode="bold">n (%)</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Diarrhea </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">6 (13) </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Vomiting </td> <td align="center" valign="top" styleCode="Botrule Rrule">2 (10) </td> <td align="center" valign="top" styleCode="Botrule Rrule">5 (11) </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Rash </td> <td align="center" valign="top" styleCode="Botrule Rrule">2 (10) </td> <td align="center" valign="top" styleCode="Botrule Rrule">4 (9) </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Hyperhidrosis </td> <td align="center" valign="top" styleCode="Botrule Rrule">1 (5) </td> <td align="center" valign="top" styleCode="Botrule Rrule">3 (7) </td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.